A Phase 2 interventional study of Pembrolizumab/Vibostolimab Co-Formulation and Pembrolizumab in Uterine Cervical Neoplasms, Endometrial Neoplasms and Squamous Cell Carcinoma of Head and Neck, sponsored by Merck Sharp & Dohme LLC. Completed at 73 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
How we know · 37 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc — 3 open to participants now, 6 under way, 2 of them phase 3. Uterine Cervical Neoplasms · Merck & Co., Inc.
Among the 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc, this one is the 18th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 26th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →3 of the 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Austria and 26 more countries
Ages 18+ · Women only
MSD Italia S.r.l. · Sites in Italy
Ages 18+ · Women only
Merck Sharp & Dohme LLC
Ages 18+
By country, each count listing its studies:
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 16 · Phase 4 2
First in 2001; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 611 is above the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 680 across the 29 interventional studies, 2,327 across the 2 observational. Of the 24 that completed or were terminated, 17 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.
Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.
1 of the studies in Uterine Cervical Neoplasms by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02628067Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | 2027-05-04 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
One of the following or cytologically confirmed, advanced (unresectable or ) solid tumors:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy.
Biological: Pembrolizumab/Vibostolimab Co-Formulation · Biological: Pembrolizumab
Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles.
Biological: Pembrolizumab
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.
Biological: Pembrolizumab/Vibostolimab Co-Formulation · Biological: Pembrolizumab · Drug: Lenvatinib
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or lenvatinib 8 mg (BW \<60 kg) qd up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.
Biological: Pembrolizumab/Vibostolimab Co-Formulation · Biological: Pembrolizumab · Drug: Lenvatinib
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with 5-Fluorouracil + Cisplatin.
Biological: Pembrolizumab/Vibostolimab Co-Formulation · Biological: Pembrolizumab · Drug: 5-Fluorouracil · Drug: Cisplatin
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Paclitaxel.
Biological: Pembrolizumab/Vibostolimab Co-Formulation · Biological: Pembrolizumab · Drug: Paclitaxel
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Gemcitabine/Cisplatin
Biological: Pembrolizumab · Drug: Cisplatin · Drug: Gemcitabine
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as local standard of care (SOC) background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Carboplatin/Paclitaxel/Bevacizumab.
Biological: Pembrolizumab · Drug: Paclitaxel · Drug: Carboplatin · Drug: Docetaxel · Drug: Bevacizumab
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Capecitabine/Oxaliplatin.
Biological: Pembrolizumab · Drug: Capecitabine · Drug: Oxaliplatin
Drug page: Vibostolimab/Pembrolizumab MK-7684AStudies of Vibostolimab/Pembrolizumab MK-7684AVibostolimab/Pembrolizumab MK-7684A pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
Also known as: MK-7684A
Pembrolizumab 200 mg administered via IV infusion Q3W.
Also known as: MK-3475, KEYTRUDA®
Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
Also known as: Lenvima, E7080, MK-7902
5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles
Also known as: 5-FU, Fluracil
Cisplatin administered via IV infusion
Also known as: Platinol, cis Platinum
Paclitaxel administered via IV infusion at investigator's choice of dose
Also known as: Taxol, Abraxane, Anzatax
Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity
Carboplatin administered via IV infusion at investigator's choice of dose and frequency
For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles
Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles
Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles
Oxaliplatin administered via IV infusion Q3W up to 35 cycles
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1
ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). The ORR was calculated using the Miettinen \& Nurminen method stratified by prior bevacizumab use interactive voice response system (IVRS). ORR as assessed by BICR in Cohort A1 is presented.
Time frame: Up to approximately 24 months
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by BICR in Cohort A1 is presented.
Time frame: Up to approximately 24 months
ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR in selected solid tumors as assessed by investigator based on RECIST 1.1 is presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). Per protocol, Cohort A1 and Cohort I were excluded in the analysis. ORR as assessed by Investigator based on RECIST 1.1 is presented.
Time frame: Up to approximately 24 months
Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months
PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-9 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 9 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 9 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.
Time frame: 9 months
PFS Per RECIST 1.1 as Assessed by Investigator at 12 Months
PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-12 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 12 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 12 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.
Time frame: 12 months
Overall Survival (OS) in Participants With Selected Solid Tumors
For Cohort A1 OS is defined as the time from randomization to death due to any cause. For Cohort A2 to Cohort J OS is defined as the time from the first dose of study intervention to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. OS in selected solid tumors is presented.
Time frame: Up to approximately 46 months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
PFS is defined as the time from first dose of study treatment to the first documented PD or death due to any cause, whichever occurs first per RECIST 1.1 by Investigator for Cohort A2 to J. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed Investigator in Cohort A2 to J is presented.
Time frame: Up to approximately 46 months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Cohort A1
For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR was presented for participants in Cohort A1.
Time frame: Up to approximately 46 months
DOR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by Investigator was presented.
Time frame: Up to approximately 46 months
ORR Per RECIST 1.1 as Assessed by Investigator in Cohort A1
ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 in Cohort A1 is presented.
Time frame: Up to approximately 24 months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants in Cohort A1
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PDPer protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by Investigator based on RECIST 1.1 in Cohort A1 is presented.
Time frame: Up to approximately 24 months
Change From Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score in Cohort A1 is presented.
Time frame: Baseline and up to Week 12
Change From Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score in Cohort A1 is presented.
Time frame: Baseline and up to Week 12
Number of Participants Who Experienced One or More Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm.
Time frame: Up to approximately 46 months
Number of Participants Who Discontinued Study Intervention Due to an AE
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm.
Time frame: Up to approximately 46 months
Initially, participants were randomly assigned (Cohort A1) or nonrandomly allocated (Cohorts A2-G). At Amendment 05, 4 new cohorts (D2, H, I, J) were added.
| Milestone | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 85 | 84 | 31 | 41 | 41 | 43 | 41 | 10 | 40 | 42 | 41 | 41 | 30 | 41 |
| Second course mk-7684a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Switch to pembrolizumab | 0 | 0 | 0 | 4 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 5 | 5 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 85 | 84 | 31 | 41 | 41 | 43 | 41 | 10 | 40 | 42 | 41 | 41 | 30 | 41 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Death | 69 | 62 | 22 | 15 | 26 | 33 | 37 | 6 | 27 | 29 | 26 | 21 | 8 | 27 |
| Withdrew: Sponsor's decision | 13 | 16 | 7 | 23 | 13 | 9 | 3 | 4 | 10 | 9 | 10 | 19 | 20 | 11 |
| Withdrew: Withdrawal by subject | 3 | 5 | 2 | 2 | 1 | 0 | 1 | 0 | 3 | 4 | 3 | 0 | 1 | 2 |
ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). The ORR was calculated using the Miettinen \& Nurminen method stratified by prior bevacizumab use interactive voice response system (IVRS). ORR as assessed by BICR in Cohort A1 is presented.
| Percentage of Participants | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab |
|---|---|---|
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1 | 20.0 (12.1 to 30.1) | 15.5 (8.5 to 25.0) |
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by BICR in Cohort A1 is presented.
| Months | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab |
|---|---|---|
| Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1 | 2.2 (2.1 to 4.2) | 2.1 (2.1 to 2.3) |
ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR in selected solid tumors as assessed by investigator based on RECIST 1.1 is presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). Per protocol, Cohort A1 and Cohort I were excluded in the analysis. ORR as assessed by Investigator based on RECIST 1.1 is presented.
| Percentage of Participants | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors | — | — | 16.1 (5.5 to 33.7) | 65.0 (48.3 to 79.4) | 42.5 (27.0 to 59.1) | 28.6 (15.7 to 44.6) | 12.5 (4.2 to 26.8) | 20.0 (2.5 to 55.6) | 52.5 (36.1 to 68.5) | 28.6 (15.7 to 44.6) | 22.0 (10.6 to 37.6) | 29.3 (16.1 to 45.5) | — | 39.0 (24.2 to 55.5) |
PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-9 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 9 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 9 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.
| Percentage of Participants | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab |
|---|---|
| Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months | 64.1 (27.9 to 85.6) |
PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-12 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 12 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 12 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.
| Percentage of Participants | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab |
|---|---|
| PFS Per RECIST 1.1 as Assessed by Investigator at 12 Months | 32.1 (7.7 to 60.4) |
For Cohort A1 OS is defined as the time from randomization to death due to any cause. For Cohort A2 to Cohort J OS is defined as the time from the first dose of study intervention to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. OS in selected solid tumors is presented.
| Months | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) in Participants With Selected Solid Tumors | 10.2 (7.2 to 15.2) | 10.3 (8.4 to 14.7) | 12.8 (7.9 to 24.0) | NA (18.6 to NA) | 22.9 (11.6 to 32.2) | 15.7 (10.6 to 19.1) | 7.0 (3.7 to 11.1) | 20.0 (6.5 to NA) | 17.8 (12.3 to 21.7) | 13.1 (8.7 to 21.7) | 19.8 (13.5 to 22.4) | 16.9 (10.3 to NA) | NA (10.0 to NA) | 12.3 (9.1 to 16.0) |
PFS is defined as the time from first dose of study treatment to the first documented PD or death due to any cause, whichever occurs first per RECIST 1.1 by Investigator for Cohort A2 to J. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed Investigator in Cohort A2 to J is presented.
| Months | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors | — | — | 2.2 (2.0 to 4.2) | 15.0 (8.1 to NA) | 6.4 (4.8 to 8.3) | 4.1 (2.3 to 8.4) | 2.4 (2.1 to 4.3) | 12.8 (4.1 to 20.5) | 10.4 (6.4 to 18.0) | 4.3 (3.9 to 6.2) | 9.2 (6.2 to 12.4) | 4.7 (2.2 to 10.5) | 10.6 (5.9 to 13.3) | 8.3 (4.4 to 10.5) |
For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR was presented for participants in Cohort A1.
| Months | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab |
|---|---|---|
| Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Cohort A1 | 10.9 (5.3 to NA) | NA (NA to NA) |
For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by Investigator was presented.
| Months | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DOR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors | — | — | 10.8 (9.6 to NA) | 21.8 (12.7 to NA) | 8.3 (4.4 to 29.8) | 12.7 (4.2 to NA) | 15.9 (5.5 to NA) | 15.6 (12.7 to NA) | 13.9 (7.9 to NA) | 10.5 (4.2 to NA) | 13.7 (6.0 to NA) | 13.1 (8.5 to NA) | — | 9.7 (6.2 to NA) |
ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 in Cohort A1 is presented.
| Percentage of Participants | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab |
|---|---|---|
| ORR Per RECIST 1.1 as Assessed by Investigator in Cohort A1 | 20.0 (12.1 to 30.1) | 16.7 (9.4 to 26.4) |
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PDPer protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by Investigator based on RECIST 1.1 in Cohort A1 is presented.
| Months | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab |
|---|---|---|
| PFS Per RECIST 1.1 as Assessed by Investigator in Participants in Cohort A1 | 2.2 (2.1 to 4.3) | 2.3 (2.1 to 4.0) |
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score in Cohort A1 is presented.
| Score on a Scale | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab |
|---|---|---|
| Change From Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1 | 0.77 (-3.84 to 5.38) | 3.53 (-1.13 to 8.20) |
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score in Cohort A1 is presented.
| Score on a scale | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab |
|---|---|---|
| Change From Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1 | -3.58 (-8.29 to 1.14) | -3.14 (-7.96 to 1.68) |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm.
| Participants | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced One or More Adverse Events (AEs) | 83 | 78 | 31 | 40 | 40 | 41 | 39 | 10 | 39 | 41 | 41 | 40 | 28 | 40 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm.
| Participants | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Intervention Due to an AE | 14 | 3 | 3 | 17 | 18 | 12 | 4 | 3 | 14 | 12 | 11 | 11 | 12 | 26 |
Collected over Up to approximately 46 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A1 MK-7684A | 71/85 (83.5%) | 43/85 (50.6%) | 79/85 (92.9%) |
| Cohort A1 Pembrolizumab | 66/84 (78.6%) | 33/83 (39.8%) | 74/83 (89.2%) |
| Cohort A2 MK-7684A | 23/31 (74.2%) | 16/31 (51.6%) | 31/31 (100%) |
| Cohort B1 MK-7684A | 15/41 (36.6%) | 23/40 (57.5%) | 40/40 (100%) |
| Cohort B1 Switch to Pembrolizumab | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Cohort B2 MK-7684A + Lenvatinib 20 mg | 26/41 (63.4%) | 27/40 (67.5%) | 40/40 (100%) |
| Cohort C MK-7684A | 34/43 (79.1%) | 16/42 (38.1%) | 39/42 (92.9%) |
| Cohort D1 MK-7684A | 37/41 (90.2%) | 21/40 (52.5%) | 37/40 (92.5%) |
| Cohort D1 Switch to Pembrolizumab | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Cohort D2 MK-7684A + Gemcitabine + Cisplatin | 6/10 (60%) | 5/10 (50%) | 10/10 (100%) |
| Cohort D2 Switch to Pembrolizumab + Gemcitabine + Cisplatin | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Cohort E MK-7684A + 5-FU + Cisplatin | 26/40 (65%) | 23/40 (57.5%) | 39/40 (97.5%) |
| Cohort E to 2nd Course MK-7684A + 5-FU + Cisplatin | 1/2 (50%) | 1/2 (50%) | 0/2 (0%) |
| Cohort E Switch to Pembrolizumab + 5-FU + Cisplatin | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Cohort F MK-7684A + Paclitaxel | 31/42 (73.8%) | 18/42 (42.9%) | 40/42 (95.2%) |
| Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | 28/41 (68.3%) | 28/41 (68.3%) | 41/41 (100%) |
| Cohort H MK-7684A | 21/41 (51.2%) | 17/41 (41.5%) | 39/41 (95.1%) |
| Cohort H Switch to Pembrolizumab | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | 8/30 (26.7%) | 12/28 (42.9%) | 28/28 (100%) |
| Cohort I Switch to Pembrolizumab + Carboplatin + Paclitaxel + Bevacizumab | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Cohort J MK-7684A + Capecitabine + Oxaliplatin | 27/41 (65.9%) | 28/41 (68.3%) | 38/41 (92.7%) |
| Cohort J Switch to Pembrolizumab + Capecitabine + Oxaliplatin | 2/6 (33.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B1 Switch to Pembrolizumab | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D1 Switch to Pembrolizumab | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort D2 Switch to Pembrolizumab + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort E to 2nd Course MK-7684A + 5-FU + Cisplatin | Cohort E Switch to Pembrolizumab + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort H Switch to Pembrolizumab | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort I Switch to Pembrolizumab + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin | Cohort J Switch to Pembrolizumab + Capecitabine + Oxaliplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Renal failureRenal and urinary disorders | 1/85 | 0/83 | 1/31 | 1/40 | 0/4 | 0/40 | 0/42 | 0/40 | 0/1 | 0/10 | 0/1 | 0/40 | 1/2 | 0/1 | 0/42 | 0/41 | 0/41 | 0/5 | 0/28 | 0/5 | 0/41 | 0/6 |
| DysphagiaGastrointestinal disorders | 0/85 | 0/83 | 0/31 | 0/40 | 0/4 | 0/40 | 1/42 | 0/40 | 0/1 | 0/10 | 0/1 | 1/40 | 0/2 | 0/1 | 0/42 | 0/41 | 0/41 | 0/5 | 0/28 | 0/5 | 0/41 | 1/6 |
| VomitingGastrointestinal disorders | 0/85 | 0/83 | 0/31 | 0/40 | 0/4 | 1/40 | 0/42 | 0/40 | 0/1 | 0/10 | 0/1 | 0/40 | 0/2 | 0/1 | 0/42 | 0/41 | 0/41 | 0/5 | 1/28 | 0/5 | 1/41 | 1/6 |
| Septic shockInfections and infestations | 3/85 | 0/83 | 1/31 | 0/40 | 0/4 | 1/40 | 0/42 | 0/40 | 0/1 | 0/10 | 0/1 | 0/40 | 0/2 | 0/1 | 1/42 | 0/41 | 0/41 | 0/5 | 0/28 | 0/5 | 0/41 | 1/6 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/85 | 0/83 | 0/31 | 0/40 | 0/4 | 0/40 | 0/42 | 0/40 | 0/1 | 0/10 | 0/1 | 0/40 | 0/2 | 0/1 | 0/42 | 0/41 | 0/41 | 0/5 | 3/28 | 0/5 | 1/41 | 0/6 |
| Urinary tract infectionInfections and infestations | 4/85 | 5/83 | 3/31 | 0/40 | 0/4 | 0/40 | 0/42 | 1/40 | 0/1 | 0/10 | 0/1 | 0/40 | 0/2 | 0/1 | 1/42 | 1/41 | 3/41 | 0/5 | 3/28 | 0/5 | 1/41 | 0/6 |
| Biliary obstructionHepatobiliary disorders | 0/85 | 0/83 | 0/31 | 0/40 | 0/4 | 0/40 | 0/42 | 1/40 | 0/1 | 1/10 | 0/1 | 0/40 | 0/2 | 0/1 | 0/42 | 0/41 | 0/41 | 0/5 | 0/28 | 0/5 | 0/41 | 0/6 |
| CholangitisHepatobiliary disorders | 0/85 | 0/83 | 0/31 | 0/40 | 0/4 | 0/40 | 0/42 | 3/40 | 0/1 | 1/10 | 0/1 | 0/40 | 0/2 | 0/1 | 0/42 | 1/41 | 0/41 | 0/5 | 0/28 | 0/5 | 0/41 | 0/6 |
| Cholangitis acuteHepatobiliary disorders | 0/85 | 0/83 | 0/31 | 0/40 | 0/4 | 0/40 | 0/42 | 0/40 | 0/1 | 1/10 | 0/1 | 0/40 | 0/2 | 0/1 | 0/42 | 0/41 | 0/41 | 0/5 | 0/28 | 0/5 | 0/41 | 0/6 |
| Cholecystitis acuteHepatobiliary disorders | 0/85 | 0/83 | 0/31 | 0/40 | 0/4 | 0/40 | 0/42 | 1/40 | 0/1 | 1/10 | 0/1 | 0/40 | 0/2 | 0/1 | 0/42 | 2/41 | 0/41 | 0/5 | 0/28 | 0/5 | 0/41 | 0/6 |
| Event | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B1 Switch to Pembrolizumab | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D1 Switch to Pembrolizumab | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort D2 Switch to Pembrolizumab + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort E to 2nd Course MK-7684A + 5-FU + Cisplatin | Cohort E Switch to Pembrolizumab + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort H Switch to Pembrolizumab | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort I Switch to Pembrolizumab + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin | Cohort J Switch to Pembrolizumab + Capecitabine + Oxaliplatin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eye pruritusEye disorders | 0/85 | 0/83 | 0/31 | 0/40 | 0/4 | 0/40 | 0/42 | 0/40 | 0/1 | 0/10 | 1/1 | 0/40 | 0/2 | 0/1 | 0/42 | 0/41 | 0/41 | 0/5 | 0/28 | 0/5 | 0/41 | 0/6 |
| Alanine aminotransferase increasedInvestigations | 12/85 | 11/83 | 3/31 | 5/40 | 0/4 | 15/40 | 6/42 | 5/40 | 0/1 | 7/10 | 1/1 | 3/40 | 0/2 | 1/1 | 9/42 | 13/41 | 4/41 | 0/5 | 6/28 | 1/5 | 20/41 | 0/6 |
| Aspartate aminotransferase increasedInvestigations | 18/85 | 11/83 | 4/31 | 5/40 | 0/4 | 14/40 | 5/42 | 6/40 | 0/1 | 4/10 | 0/1 | 3/40 | 0/2 | 1/1 | 7/42 | 17/41 | 3/41 | 0/5 | 6/28 | 1/5 | 22/41 | 0/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/85 | 7/83 | 0/31 | 10/40 | 0/4 | 4/40 | 4/42 | 1/40 | 0/1 | 4/10 | 1/1 | 4/40 | 0/2 | 0/1 | 6/42 | 8/41 | 7/41 | 0/5 | 4/28 | 1/5 | 3/41 | 0/6 |
| DysuriaRenal and urinary disorders | 9/85 | 4/83 | 0/31 | 3/40 | 1/4 | 2/40 | 0/42 | 1/40 | 0/1 | 0/10 | 1/1 | 0/40 | 0/2 | 0/1 | 1/42 | 0/41 | 1/41 | 0/5 | 1/28 | 0/5 | 0/41 | 0/6 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 8/85 | 5/83 | 1/31 | 9/40 | 0/4 | 6/40 | 2/42 | 2/40 | 0/1 | 4/10 | 1/1 | 2/40 | 0/2 | 0/1 | 7/42 | 4/41 | 5/41 | 0/5 | 4/28 | 0/5 | 4/41 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 38/85 | 35/83 | 11/31 | 13/40 | 1/4 | 8/40 | 9/42 | 10/40 | 0/1 | 8/10 | 0/1 | 23/40 | 0/2 | 0/1 | 20/42 | 12/41 | 10/41 | 0/5 | 16/28 | 0/5 | 20/41 | 1/6 |
| ConstipationGastrointestinal disorders | 17/85 | 16/83 | 6/31 | 10/40 | 0/4 | 4/40 | 6/42 | 3/40 | 0/1 | 6/10 | 0/1 | 8/40 | 0/2 | 0/1 | 8/42 | 5/41 | 4/41 | 0/5 | 6/28 | 0/5 | 6/41 | 0/6 |
| NauseaGastrointestinal disorders | 17/85 | 10/83 | 12/31 | 17/40 | 0/4 | 12/40 | 7/42 | 6/40 | 0/1 | 6/10 | 0/1 | 18/40 | 0/2 | 0/1 | 11/42 | 17/41 | 1/41 | 0/5 | 10/28 | 0/5 | 14/41 | 0/6 |
| FatigueGeneral disorders | 13/85 | 15/83 | 5/31 | 13/40 | 0/4 | 14/40 | 9/42 | 13/40 | 0/1 | 6/10 | 0/1 | 17/40 | 0/2 | 0/1 | 9/42 | 22/41 | 6/41 | 0/5 | 6/28 | 0/5 | 18/41 | 1/6 |
| Age, Continuous(Years) | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 53.1 ± 11.7 | 49.4 ± 10.9 | 53.8 ± 13.1 | 63.2 ± 7.3 | 66.7 ± 7.6 | 61.9 ± 9.7 | 61.8 ± 12.2 | 58.6 ± 10.8 | 62.8 ± 10.5 | 51.8 ± 13.3 | 66.3 ± 11.8 | 74.4 ± 9.0 | 64.0 ± 13.0 | 62.5 ± 12.2 | 59.5 ± 13.0 |
| Sex: Female, Male(Participants) | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 85 | 84 | 31 | 41 | 41 | 6 | 23 | 8 | 5 | 42 | 14 | 9 | 30 | 13 | 432 |
| Male | 0 | 0 | 0 | 0 | 0 | 37 | 18 | 2 | 35 | 0 | 27 | 32 | 0 | 28 | 179 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 27 | 18 | 6 | 12 | 3 | 7 | 7 | 6 | 5 | 18 | 21 | 12 | 9 | 29 | 180 |
| Not Hispanic or Latino | 39 | 44 | 18 | 20 | 31 | 23 | 31 | 2 | 33 | 23 | 18 | 29 | 15 | 11 | 337 |
| Unknown or Not Reported | 19 | 22 | 7 | 9 | 7 | 13 | 3 | 2 | 2 | 1 | 2 | 0 | 6 | 1 | 94 |
| Race (NIH/OMB)(Participants) | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 14 | 14 | 8 | 1 | 7 | 15 | 14 | 2 | 9 | 1 | 5 | 13 | 1 | 5 | 109 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 54 | 47 | 15 | 31 | 27 | 16 | 24 | 6 | 27 | 37 | 32 | 23 | 16 | 32 | 387 |
| More than one race | 1 | 6 | 2 | 4 | 1 | 0 | 0 | 1 | 3 | 3 | 2 | 5 | 6 | 3 | 37 |
| Unknown or Not Reported | 15 | 17 | 6 | 4 | 6 | 12 | 3 | 1 | 1 | 1 | 2 | 0 | 7 | 1 | 76 |
| Investigator Choice of Use of Bevacizumab(Count of Participants) | Cohort A1 MK-7684A | Cohort A1 Pembrolizumab | Cohort A2 MK-7684A | Cohort B1 MK-7684A | Cohort B2 MK-7684A + Lenvatinib 20 mg | Cohort C MK-7684A | Cohort D1 MK-7684A | Cohort D2 MK-7684A + Gemcitabine + Cisplatin | Cohort E MK-7684A + 5-FU + Cisplatin | Cohort F MK-7684A + Paclitaxel | Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg | Cohort H MK-7684A | Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab | Cohort J MK-7684A + Capecitabine + Oxaliplatin | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | 40 | 40 | — | — | — | — | — | — | — | — | — | — | — | — | 80 |
| No | 45 | 44 | — | — | — | — | — | — | — | — | — | — | — | — | 89 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2021 to primary completion in Aug 2025, 46 months.
Results were first posted in Sep 2026, 1 year 1 month after primary completion.
Of 50 industry-sponsored phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 46. This study's 46 months is above that.
Counting every sponsor, half of 205 studies reached it within 42 months; a quarter within 29 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vibostolimab/Pembrolizumab MK-7684A